title: Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals.
abstract: Rapid, large-scale manufacture of medical countermeasures can be uniquely met by the plant-made-pharmaceutical platform technology. As a participant in the Defense Advanced Research Projects Agency (DARPA) Blue Angel project, the Caliber Biotherapeutics facility was designed, constructed, commissioned and released a therapeutic target (H1N1 influenza subunit vaccine) in <18 months from groundbreaking. As of 2015, this facility was one of the world's largest plant-based manufacturing facilities, with the capacity to process over 3500 kg of plant biomass per week in an automated multilevel growing environment using proprietary LED lighting. The facility can commission additional plant grow rooms that are already built to double this capacity. In addition to the commercial-scale manufacturing facility, a pilot production facility was designed based on the large-scale manufacturing specifications as a way to integrate product development and technology transfer. The primary research, development and manufacturing system employs vacuum-infiltrated Nicotiana benthamiana plants grown in a fully contained, hydroponic system for transient expression of recombinant proteins. This expression platform has been linked to a downstream process system, analytical characterization, and assessment of biological activity. This integrated approach has demonstrated rapid, high-quality production of therapeutic monoclonal antibody targets, including a panel of rituximab biosimilar/biobetter molecules and antiviral antibodies against influenza and dengue fever.
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Barry R
authors.initials: BR
authors.lastname: Holtz
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Berquist
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Lindsay D
authors.initials: LD
authors.lastname: Bennett
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Vally J M
authors.initials: VJ
authors.lastname: Kommineni
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Ranjith K
authors.initials: RK
authors.lastname: Munigunti
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Earl L
authors.initials: EL
authors.lastname: White
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Don C
authors.initials: DC
authors.lastname: Wilkerson
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Kah-Yat I
authors.initials: KY
authors.lastname: Wong
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Lan H
authors.initials: LH
authors.lastname: Ly
authors.affiliation: Caliber Biotherapeutics, Bryan, TX, USA.
authors.forename: Sylvain
authors.initials: S
authors.lastname: Marcel
mesh_terms: D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D001691:Biological Therapy / Q000191:economics*; D001709:Biotechnology; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics* / Q000378:metabolism*; D010944:Plants / Q000235:genetics / Q000378:metabolism*; D030821:Plants, Genetically Modified
chemical_list: D000911:Antibodies, Monoclonal; D004364:Pharmaceutical Preparations
keywords: Nicotiana benthamiana; manufacturing; monoclonal antibodies; plant-made pharmaceuticals; transient expression; vaccine